UPB_OUT_1 [2025-04-04 04:59:02 -0400] 3165 Bytes | 841 tokens | Cum: 841 tkns (10.51% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Upstream Bio (UPB) which is at 7.2 up from 6.3. So, I pulled together a bunch of data for you to look over real fast. It's still early, 4:59:01 AM on Fri Apr 04, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Upstream Bio (UPB)
IPO: 2024-10-11 (5 Months Ago)
Market Cap: $359,393,996
Shares Outstanding: 53,640,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.

Here’s the first list of news for Upstream Bio:

C1 - Mar-12-25 07:00AM - Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
C2 - Feb-25-25 08:00AM - Upstream Bio to Present at Upcoming March Investor Conferences
C3 - Feb-11-25 09:00AM - Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps
C4 - Jan-06-25 08:00AM - Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
C5 - Dec-17-24 08:00AM - Upstream Bio Appoints Allison Ambrose as General Counsel
C6 - Dec-16-24 08:00AM - Upstream Bio Announces Addition to Russell 2000 Index
C7 - Nov-21-24 08:00AM - Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
C8 - Nov-08-24 07:11AM - Upstream Bio reports Q3 revenue $607,000 vs $621,000 last year

Prior AI Reports for UPB:
1. 2025-04-01 – Score: 45 – Target: 7.6500 – Highs: 6.7160 / 6.8550 / 6.72
high-insider-ownership-and-short-interest-create-uncertain-outlook-for-upstream-bio

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Upstream Bio (UPB).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

UPB_OUT_3 [2025-04-04 04:59:07 -0400] 1107 Bytes | 315 tokens | Cum: 1158 tkns (14.47% of 8k)
==========================================================================

Showing C1 (chunk 1 of 10): C1:
**Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights**
Date: Mar-12-25 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/12/3041224/0/en/Upstream-Bio-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Business-Highlights.html

March 12, 2025 07:00 ET| Source:Upstream BioUpstream Bio

– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –

– Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 –

WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, to

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

UPB_OUT_5 [2025-04-04 04:59:08 -0400] 901 Bytes | 299 tokens | Cum: 1545 tkns (19.31% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T05:32:15Z - Upstream Bio, Inc.'s Lock-Up Period Will Expire on April 9th (NASDAQ:UPB)...
A2 - 2025-04-01T13:06:00Z - Pre-market Movers: GATE, ICCT, GPUS, UPB, INNV....
A3 - 2025-03-30T07:08:28Z - Charles Schwab Investment Management Inc. Invests $2.23 Million in Upstream Bio, Inc. (NASDAQ:UPB)...
A4 - 2025-03-27T07:10:47Z - Bank of New York Mellon Corp Invests $607,000 in Upstream Bio, Inc. (NASDAQ:UPB)...
A5 - 2025-03-19T16:57:21Z - Upstream Bio (NASDAQ:UPB) Stock Price Down 7.3% - Time to Sell?...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

UPB_OUT_7 [2025-04-04 04:59:13 -0400] 1098 Bytes | 335 tokens | Cum: 1882 tkns (23.52% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Upstream Bio, Inc.'s Lock-Up Period Will Expire on April 9th (NASDAQ:UPB)**Date: 2025-04-03Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/upstream-bio-incs-lock-up-period-will-expire-on-april-9th-nasdaqupb-2025-04-02/Upstream Bio's (NASDAQ:UPB - Get Free Report) lock-up period is set to end on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Shares of UPB stock opened at $6.70 on Wednesday. Upstream Bio has a 52-week low of $5.85 and a 52-week high of $29.46. The stock has a 50-day moving average price of $8.45.

Institution

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

UPB_OUT_9 [2025-04-04 04:59:13 -0400] 267 Bytes | 67 tokens | Cum: 2082 tkns (26.02% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

UPB_OUT_11 [2025-04-04 04:59:16 -0400] 253 Bytes | 85 tokens | Cum: 2169 tkns (27.11% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
Document B1 not found. Only 0 articles available.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

UPB_OUT_13 [2025-04-04 04:59:16 -0400] 1070 Bytes | 265 tokens | Cum: 2474 tkns (30.93% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-12 10-K Item 7. Mgts Discus sion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and the related notes a...

S2 - 2025-03-12 8-K Item 2.02 Results of Oper and Fin Cond.

On March 12, 2025, Upstream Bio, Inc. (the Company) announced its financial results and business highlights for the quarter and year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 ...

S3 - 2025-03-12 10-K Item 7. Mgts Discus sion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and the related notes a...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

UPB_OUT_15 [2025-04-04 04:59:17 -0400] 1098 Bytes | 228 tokens | Cum: 2704 tkns (33.80% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discus sion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K (this Annual Report). Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review "Item 1A, Risk Factors" of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in th

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

UPB_OUT_17 [2025-04-04 04:59:21 -0400] 1098 Bytes | 225 tokens | Cum: 2931 tkns (36.64% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): e following discussion and analysis. Please also see the section titled Special note regarding forward-looking statements included elsewhere in this Annual Report.

Overview

We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Preclinical and clinical data to date demonstrate verekitugs highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended do

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

UPB_OUT_19 [2025-04-04 04:59:34 -0400] 5604 Bytes | 1569 tokens | Cum: 4605 tkns (57.56% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+------------------------+
| Volume: 234,251 | Perf Month: -25.62% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 251.84K | Perf Quarter: -61.68% | Short Float: 19.39% | ROE: - |
+---------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.93 | Index: RUT | Short Ratio: 14.74 | ROI: - |
+---------------------+-----------------------+------------------------+------------------------+
| RSI (14): 34.43 | Market Cap: 337.94M | Short Interest: 3.71M | Sales Surprise: 59.30% |
+---------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.79 | Shs Outstand: 53.60M | Beta: - | EPS Surprise: 22.72% |
+---------------------+-----------------------+------------------------+------------------------+
| SMA20: -20.44% | Shs Float: 19.15M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+------------------------+
| SMA50: -24.40% | Inst Own: 40.23% | Sales past 5Y: 47.97% | Earnings: Mar 12 BMO |
+---------------------+-----------------------+------------------------+------------------------+
| SMA200: -59.32% | Insider Own: 64.29% | Employees: 52 | |
+---------------------+-----------------------+------------------------+------------------------+
| Perf Week: -7.49% | Insider Trans: 8.92% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: Upstream Bio, Inc. (UPB) by Ambrose Allison (General Counsel) on 2025-02-06
- Stock Option (Right to Buy): 25000 shares at $0 (D)

Inside Trans: Upstream Bio, Inc. (UPB) by Deykin Aaron (Chief Medical Officer) on 2025-02-06
- Stock Option (Right to Buy): 165000 shares at $0 (D)

Inside Trans: Upstream Bio, Inc. (UPB) by Houghton Adam (Chief Business Officer) on 2025-02-06
- Stock Option (Right to Buy): 140000 shares at $0 (D)

Inside Trans: Upstream Bio, Inc. (UPB) by GRAY MICHAEL (CFO and COO) on 2025-02-06
- Stock Option (Right to Buy): 195000 shares at $0 (D)

Inside Trans: Upstream Bio, Inc. (UPB) by Sutherland Everett Rand (Chief Executive Officer) on 2025-02-06
- Stock Option (Right to Buy): 500000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 2370000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -62806000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 6.3
Average Volume: 245735.41
30-Day High: 9.87
30-Day Low: 6.12

[Detailed Financials: TTM 2024]
- Total Assets: $481,719,000.0
- Total Liabilities: $11,867,000.0
- Total Equity: $469,852,000.0
- Current Assets: $479,160,000.0
- Current Liabilities: $10,737,000.0

[Income Statement: TTM 2024]
- Revenue: $2,370,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.58

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $300,253,000.0

[Detailed Financials: FY 2024]
- Total Assets: $481,719,000.0
- Total Liabilities: $11,867,000.0
- Total Equity: $469,852,000.0
- Current Assets: $479,160,000.0
- Current Liabilities: $10,737,000.0

[Income Statement: FY 2024]
- Revenue: $2,370,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.58

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $300,253,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

UPB_OUT_21 [2025-04-04 04:59:36 -0400] 687 Bytes | 169 tokens | Cum: 5031 tkns (62.89% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

UPB_IN_23 [2025-04-04 04:59:36 -0400] 126 Bytes | 29 tokens | Cum: 5090 tkns (63.62% of 8k)
==========================================================================

====================================
[2025-04-04 04:59:36] # Analysis Completed
Elapsed Time: 35.13 seconds